ScreenerHero

CRDLCardiol Therapeutics Inc. Class A Common Shares

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · cardiolrx.com
1.860USDMkt Cap: 217.29M $P/E: —

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx,…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap217.29M $
Enterprise Value191.32M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.82M $
Revenue/Share—
Last Price1.860 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.45
PEG—
EV/EBITDA-5.34
EV/Revenue—
P/S—
P/B12.46
EPS (TTM)-0.25
EPS (Forward)-0.22
52W Range
1.8557% of range1.932
52W High1.932 USD
52W Low1.855 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-189.17%
ROA-143.18%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.85M $
CapEx (TTM)24.48K $
FCF Margin—
FCF Yield-7.12%
Net Debt-25.97M $
Net Debt/EBITDA0.72
Balance Sheet
Debt/Equity0.01
Current Ratio5.55
Quick Ratio5.01
Book Value/Sh0.1492 USD
Cash/Share0.2230 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.938 USD
Upside (mean)+326.7%
Target Range4.976 USD – 10.07 USD
$4.976+326.7% to mean$10.07
# Analysts4
Ownership
Shares Out.116.82M
Float92.10M
Insiders2.37%
Institutions25.91%
Short Interest
Short Ratio2.5d
Short % Float2.01%
Short % Out.1.95%
Shares Short2.25M
Short (prev mo.)2.22M
Technical
SMA 501.258 (+47.8%)
SMA 2001.155 (+61.1%)
Beta0.47
S&P 52W Chg19.18%
Avg Vol (30d)746.75K
Avg Vol (10d)1.49M
Technical Indicators
RSI (14)76.2
MACD0.1898
MACD Signal0.1492
MACD Hist.+0.0407
BB Upper2.060 USD
BB Middle1.509 USD
BB Lower0.9572 USD
BB Width73.12%
ATR (14)0.1164 USD
Vol Ratio (20d)0.63x